Pharma 3.

0 Business Model’s
Effects on the Supply Chain
Metin Durakoğlu
2013712372
Advisor: Prof. Dr. Taner Bilgiç
 Project Goals
• Determining commercial excellence of Pharma 3.0
business model in pharmaceutical market and its
importance for supply chain activities,
• Specifying the current situation in the market and
comparing it with future,
• Performing interviews with supply chain managers and
other third parties in the sector about development of
supply chain by the aid of Pharma 3.0 business model,
• Assessing the challenges and possible risks in supply
chain dynamics for pharmaceutical sector and
recommendations for risk mitigation.
 Problems with Pharma 1.0
• The patent problems
• Pricing pressures
• Increasing focus on comparative effectiveness
• Globalization and robust growth in emerging
markets
• The progression toward personalized medicine
• Growing consumerism
 Problems with Pharma 2.0
• Despite the great effects in sector (less market
risks because of diversified portfolio) some
problems occurred.
 No solution for long term
 Similar to Pharma 1.0
 Not a patient-centric model, just about
providing diversification of portfolios
 Pharma 3.0 Business Model
• Changing ecosystems compared to Pharma 1.0
and Pharma 2.0
• Building the future via innovative
collaborations
• Rather than just focusing on patient’s health,
providing products and services which are
particularly designed for health improvement
• Patient-centric viewpoint = consumerism
revolution
 Pharma 3.0 Business Model
• New transformative trends especially in health
IT, personalized medicine and emerging
markets
• Development of social media
• Importance of big data about data mining and
patient feedback
The Changing Landscape of
Healthcare
 Implementations of Pharma 3.0
Chip-in-the-pill technology

Nintendo DS glucosemeter
Mission: Building The Best Supply Chain
Strategy
Quality a
competitive
advantage:
Prevention is key
Enable business
growth through
innovation
Drive customer
satisfaction through E2E
alignment
Execute with excellence:
Reliability & Sustainability
Build a responsive, agile and
diverse organization
 Expectations of External Partners
(Interconnectedness through Value Alignment)
Main Supply Chain Activities
Development of Supply Chain in Pharma
Industry
• New formulation technologies
 Pill-based versions of some proteins
 Biologics and biosimilars
• New manufacturing technologies
 Flexible processes instead of traditional ones
 Miniaturized, modular components
• New distribution technologies (data sharing,
monitoring products)
• New patient interface technologies (Pharma 3.0’s
new technologies)
• Greater collaboration
Supply Chains’ Situations
Supply Chain Transformation
Building Alliance Network Partnerships
Pharma 3.0 Project Examples &
Implications in Supply Chain
Implications in Supply
Organizations Project Initiatives
Chain
Collaboration in R&D to Overall reduction in
identify early stages in related costs &
Alzheimer’s disease simplification

Launching of health Accuracy in forecasting

reports about anti- supply and demand
malarial drugs through parameters &
mobile phones improved operation

Partnerships to develop New R&D approaches to

and commercialize the enter the rare disease
treatment of Gaucher market
disease
 Project Methodology
• Detailed description of Pharma 3.0 business
model
• Comparison of Pharma 3.0 with other models
• Importance of Pharma 3.0 for supply chain
activities
• Development of local and global supply chain
and main trends
• Probable supply chain strategies for the future
(according to results of interviews)